Hefeng Wang

Dr. Hefeng Wang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2021 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
GWGang Wang
Gang Wang
HWHefeng Wang
Hefeng Wang
LZLijuan Zhang
Lijuan Zhang
FGFeng Guo
Feng Guo
XWXiangyu Wu
Xiangyu Wu
YLYang Liu
Yang Liu

15 September 2022 in Frontiers in Microbiology
Verified
Journal Article
Open access
XLXiuyun Li
Xiuyun Li
JZJing Zhao
Jing Zhao
BZBin Zhang
Bin Zhang
XDXuexia Duan
Xuexia Duan
JJJin Jiao
Jin Jiao
HWHefeng Wang
Hefeng Wang
β-Lactams have been a clinical focus since their emergence and indeed act as a powerful tool to combat severe bacterial infections, but their effectiveness is threatened by drug resistance in bacteria, primarily by the production of serine- and metallo-β-lactamases. Although once of less clinical relevance, metallo-β-lactamases are now increasingly threatening. The rapid dissemination of resistance mediated by metallo-β-lactamases poses an increasing challenge to public health worldwide and comprises most existing antibacterial chemotherapies. Regrettably, there have been no clinically available inhibitors of metallo-β-lactamases until now. To cope with this unique challenge, researchers are exploring multidimensional strategies to combat metallo-β-lactamases. Several studies have been conducted to develop new drug candidates or calibrate already available drugs against metallo-β-lactamases. To provide an overview of this field and inspire more researchers to explore it further, we outline some promising candidates targeting metallo-β-lactamase producers, with a focus on Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. Promising candidates in this review are composed of new antibacterial drugs, non-antibacterial drugs, antimicrobial peptides, natural products, and zinc chelators, as well as their combinations with existing antibiotics. This review may provide ideas and insight for others to explore candidate metallo-β-lactamases as well as promote the improvement of existing data to obtain further convincing evidence.

17 May 2024 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
XLXiuyun Li
Xiuyun Li
JCJie Cai
Jie Cai
XDXimeng Duan
Ximeng Duan
YZYamin Zhang
Yamin Zhang
MCMin Cui
Min Cui
HWHefeng Wang
Hefeng Wang

12 August 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
XLXiuyun Li
Xiuyun Li
HMHao Meng
Hao Meng
HWHefeng Wang
Hefeng Wang
YZYujing Zhang
Yujing Zhang
WYWanpeng Yu
Wanpeng Yu
Indoleamine 2,3-dioxygenase 1 (IDO1) has emerged as a critical immunometabolic regulator in cancer, orchestrating immunosuppression through its rate-limiting catabolism of tryptophan to kynurenine. This enzymatic activity establishes an immunosuppressive tumor microenvironment via two distinct pathways: GCN2-mediated T cell anergy resulting from tryptophan depletion, and AhR-dependent immune tolerance induced by accumulating kynurenine metabolites. The therapeutic landscape of IDO1 inhibition has progressed significantly from early heme-competitive inhibitors like epacadostat to next-generation proteolysis-targeting chimera (PROTAC) technology. While over 20 small-molecule IDO1 inhibitors have entered clinical trials for various cancers, their variable efficacy has underscored the need for improved target engagement strategies and better patient selection biomarkers. PROTACs represent a paradigm shift in IDO1 modulation, offering the unique advantage of complete target degradation rather than mere inhibition. This review systematically evaluates: (1) clinically investigated IDO1 inhibitors and their pharmacological profiles, and (2) the preclinical promise of IDO1-targeting PROTAC degraders. Through critical analysis of their mechanisms of action and therapeutic potential, we provide insights into optimizing IDO1-targeted strategies for cancer immunotherapy.

2 December 2022 in Asian Journal of Andrology
Verified
Journal Article
Open access
XLXiu-Yun Li
Xiu-Yun Li
MZMei-Hua Zhang
Mei-Hua Zhang
ZCZhao-Wen Chen
Zhao-Wen Chen
BZBin Zhang
Bin Zhang
GBGang Bai
Gang Bai
HWHefeng Wang
Hefeng Wang
This study assessed the effects of a simulated high-altitude environment on the reproductive system of prepubertal male rats and the reversibility of these effects upon return to a normal environment. Three-week-old male Wistar rats were randomly allocated to 4 groups that were exposed to different conditions: a normal environment for 6 weeks and 12 weeks, respectively, hypobaric hypoxia for 6 weeks, and hypobaric hypoxia for 6 weeks followed by a normal environment for 6 weeks. Multiple pathophysiological parameters were evaluated at the histological, endocrine, and molecular levels. Hypobaric hypoxia exposure for 6 weeks during the prepubertal phase significantly altered physiological parameters, body functions, blood indices, and reproductive potential. Six weeks after returning to a normal environment, the damaged reproductive functions partially recovered due to compensatory mechanisms. However, several changes were not reversed after returning to a normal environment for 6 weeks, including disorders of body development and metabolism, increased red blood cells, increased fasting blood glucose, abnormal blood lipid metabolism, decreased testicular and epididymis weights, abnormal reproductive hormone levels, excessive apoptosis of reproductive cells, and decreased sperm concentration. In summary, a hypobaric hypoxic environment significantly impaired the reproductive function of prepubertal male rats, and a return to normal conditions during the postpubertal phase did not fully recover these impairments.